Mutant-selective PI3K-alpha H1047R Inhibitor LOXO-783 clinical trials
Also written LY3849524 and LOXO-783.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses Mutant-selective PI3K-alpha H1047R Inhibitor LOXO-783 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses Mutant-selective PI3K-alpha H1047R Inhibitor LOXO-783 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsActive, not recruitingPhase 1Eli Lilly and CompanyNCT05307705Written as LOXO-783
- A Study to Evaluate the Effect of Food on LOXO-783 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06028425Written as LOXO-783
- A Study of [14C]-LOXO-783 in Healthy Adult ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06102512Written as [¹⁴C]-LOXO-783
- A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05894928Written as LOXO-783